Betahistine Treatment for Vertigo

Introduction to Betahistine Dosing

The American Academy of Otolaryngology-Head and Neck Surgery recommends starting betahistine at 48 mg daily, with treatment continuing for at least 3 months and reassessment at 6-9 months to determine if continuation is warranted 1, 2

Initial dose of betahistine should be 48 mg daily, administered either as 24 mg twice daily or as a single 48 mg modified-release tablet, with a minimum treatment duration of 3 months to properly evaluate therapeutic efficacy 1, 2
Reassessment should occur at 6-9 months, and if no improvement occurs by this time, betahistine should be discontinued as continued therapy is unlikely to provide benefit 1, 2, 3

The American Academy of Otolaryngology-Head and Neck Surgery explicitly states they cannot make a definitive recommendation for betahistine use in Meniere's disease due to conflicting evidence, with the high-quality BEMED trial finding no significant difference between betahistine and placebo in reducing vertigo attacks over 9 months 1, 2, 3
Higher doses of betahistine (144 mg/day) show no advantage over the standard 48 mg/day dose 1, 2

Betahistine is absolutely contraindicated in patients with pheochromocytoma 1, 2, 3
Relative contraindications for betahistine use include asthma and active peptic ulcer disease, and it should be used with caution in these cases 1, 2, 3
Common side effects of betahistine include headache, balance disorder, nausea, and upper gastrointestinal symptoms, as well as nasopharyngitis, feeling hot, eye irritation, and palpitations 1, 2, 3

The American Academy of Otolaryngology-Head and Neck Surgery recommends confirming true vertigo rather than vague dizziness or lightheadedness before initiating betahistine treatment, as betahistine is indicated for vestibular disorders 4, 5
Screening for contraindications such as pheochromocytoma, active asthma, and peptic ulcer disease is necessary before starting betahistine 1, 2, 3
Initiation of 48 mg daily betahistine, reassessment at 3 months, and continuation to 6-9 months if partial response or stable symptoms are recommended 1, 2

For acute vertigo episodes, medications with direct antiemetic effects like prochlorperazine are preferred over betahistine 2
Intratympanic steroids combined with oral betahistine may improve vertigo control, with 73% improvement vs 44% without betahistine 1
For refractory Meniere's disease, intratympanic gentamicin provides 70-87% complete vertigo control, though with a 12.5-15.4% risk of hearing loss 1

The American Academy of Otolaryngology‑Head and Neck Surgery notes that betahistine can be offered as a maintenance medication to lessen chronic vestibular symptoms or to help prevent future vertigo attacks in patients with definite Ménière’s disease, with the decision weighing expected benefits against potential harms【6】. (Evidence strength not explicitly stated in the source.)